Antiangiogenic therapies in colorectal cancer

SummaryAngiogenesis is a  very important step in the development of cancer. Several antiangiogenic biological agents have
been studied during the past two decades for the treatment of colorectal cancer, both in adjuvant and metastatic
settings. The first and most intensively studied is bevacizumab, a  humanized monoclonal antibody against the vascular
endothelial growth factor. Since its approval in 2004, other antiangiogenic agents have been evaluated in clinical trials
and some subsequently approved for the treatment of metastatic colorectal cancer such as aflibercept, ram ucirumab, and
regorafenib. In general, antiangiogenic agents show a modest efficacy in patients with metastatic colorectal cancer but
not in the adjuvant setting. Also, there are no predictive biomarkers that could aid in selecting responsive patients. In
this revie w we summarize the results of the completed large clinical trials investigating the efficacy of antiangiogenic
therapies in colorectal cancer.

Source: Memo - Magazine of European Medical Oncology - October 25, 2017 Category: Cancer & Oncology Source Type: research